Biomarkers and the quadriceps femoris muscle architecture assessed by ultrasound in older adults with heart failure with preserved ejection fraction: a cross-sectional study
Open Access
- 8 August 2022
- journal article
- research article
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 34 (10) , 2493-2504
Abstract
Background: Sarcopenia is an important comorbidity in patients with heart failure with preserved ejection fraction (HFpEF). The ultrasound (US) assessment has all the advantages of being used in primary care to assess muscle quantity and quality. Some biomarkers could be indicative of muscle mass loss. Aims: To describe the quantitative and qualitative characteristics of the quadriceps femoris assessed by US in older adults with HFpEF and to assess the relationship of the blood and urinary biomarkers, the polypharmacy and comorbidities with US outcomes in older adults with HFpEF. Methods: A cross-sectional study was conducted. 76 older adults with HFpEF were included. The quadriceps femoris muscle thickness (MT, cm), the subcutaneous fat tissue thickness (FT, cm), the muscle echo intensity (MEI) and the subcutaneous fat tissue echo intensity (FEI) were assessed by US in a non-contraction (non-con) and contraction (con) situations. Polypharmacy, comorbidities, blood and urine biomarkers were also collected. Results: The carbohydrate antigen 125 (CA-125), the folic acid and the urine creatinine shared the 86.6% variance in the non-con MT, adjusted by age, sex and body mass index (BMI). The folic acid shared the 38.5% of the variance in the con MT, adjusted by age, sex and BMI. The glycosylated haemoglobin explained the 39.6% variance in the non-con MEI, adjusted by age, sex and BMI. The chlorine (Cl−) explained the 40.2% of the variance in the non-con FT, adjusted by age, sex and BMI. The polypharmacy and the folic acid explained the 37.9% of variance in the non-con FEI, while the polypharmacy and the thyrotropin (TSH) shared the 44.4% of variance in the con FEI, both adjusted by age, sex and BMI. No comorbidities, polypharmacy, or blood and urinary biomarkers could explain the con MEI and the con FT variance. Conclusions: Blood and urinary biomarkers obtained in routine analyses could help clinicians detect US outcome changes in older adults with HFpEF and identify a worsening of sarcopenia. Trial registration: NCT03909919. April 10, 2019. Retrospectively registered.Keywords
Funding Information
- Universidad de Málaga
This publication has 78 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Echo intensity obtained from ultrasonography images reflecting muscle strength in elderly menClinical Interventions in Aging, 2013
- Impact of nutrition on muscle mass, strength, and performance in older adultsOsteoporosis International, 2012
- Relation of Carbohydrate Antigen-125 to Left Atrial Remodeling and its Prognostic Usefulness in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction in WomenThe American Journal of Cardiology, 2012
- Late onset oculopharyngeal muscular dystrophy with prominent neurogenic features and short GCG trinucleotide expansionMuscle & Nerve, 2010
- New normal values for quantitative muscle ultrasound: Obesity increases muscle echo intensityMuscle & Nerve, 2010
- Body composition in patients with non−small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysisThe American Journal of Clinical Nutrition, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failureEuropean Journal of Preventive Cardiology, 2004
- Reliability of B‐mode ultrasound for the measurement of body fat and muscle thicknessAmerican Journal of Human Biology, 1992